Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Ultra-high Risk
100%
High-risk Myeloma
100%
High-risk Cytogenetics
75%
Very Good Partial Response
62%
Hazard Ratio
50%
Minimal Residual Disease
50%
Overall Survival
37%
Median Progression-free Survival
37%
Multiple Myeloma Patients
37%
Progression-free Survival
25%
Pretransplant
25%
Lenalidomide
25%
Del17p
25%
MD Anderson Cancer Center
12%
Fluorescence in Situ Hybridization
12%
Chart Review
12%
High Risk
12%
Standard of Care
12%
Median Overall Survival
12%
Multivariate Analysis
12%
Survival Outcomes
12%
Clinical Trials
12%
Bortezomib
12%
Adult Patients
12%
Single Center
12%
New Treatment Options
12%
Cytogenetic Aberrations
12%
Early Use
12%
Induction Therapy
12%
Maintenance Therapy
12%
Review Analysis
12%
Carfilzomib
12%
Newly Diagnosed multiple Myeloma
12%
Male Sex
12%
Bispecific Antibody
12%
1q21 Amplification
12%
Chimeric Antigen Receptor T-cell Therapy
12%
T Cell Bispecific
12%
1q21 Gain
12%
Medicine and Dentistry
Multiple Myeloma
100%
Autologous Stem Cell Transplantation
100%
Autologous Hematopoietic Stem Cell Transplantation
87%
Progression Free Survival
62%
Hazard Ratio
50%
Overall Survival
50%
Minimal Residual Disease
50%
Dexamethasone
25%
Lenalidomide
25%
Malignant Neoplasm
12%
Clinical Trial
12%
Multivariate Analysis
12%
Fluorescence in Situ Hybridization
12%
Maintenance Therapy
12%
Bortezomib
12%
Carfilzomib
12%
Bispecific Antibody
12%
Chimeric Antigen Receptor T-Cell Immunotherapy
12%
Biochemistry, Genetics and Molecular Biology
Autologous Stem Cell Transplantation
100%
Autologous Hematopoietic Stem Cell Transplantation
100%
Cytogenetics
85%
Progression Free Survival
71%
Overall Survival
57%
Dexamethasone
28%
Fluorescence in Situ Hybridization
14%
Clinical Trial
14%
T Cell
14%
Multivariate Analysis
14%
Chimeric Antigen Receptor
14%
Immunology and Microbiology
Multiple Myeloma
100%
Autologous Stem Cell Transplantation
100%
Autologous Hematopoietic Stem Cell Transplantation
87%
Progression Free Survival
62%
Overall Survival
50%
Dexamethasone
25%
Lenalidomide
25%
Fluorescence in Situ Hybridization
12%
Bispecific Antibody
12%
Chimeric Antigen Receptor T-Cell Therapy
12%
Neuroscience
Stem Cell
100%
Hematopoietic Cell
100%
Cytogenetics
85%
Dexamethasone
28%
Lenalidomide
28%
T Cell
14%
In Situ Hybridization
14%
Bortezomib
14%
Cell Therapy
14%
Carfilzomib
14%
Chimeric Antigen Receptor
14%
Bispecific Antibody
14%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Progression Free Survival
62%
Overall Survival
50%
Minimal Residual Disease
50%
Dexamethasone
25%
Lenalidomide
25%
Malignant Neoplasm
12%
Clinical Trial
12%
Bortezomib
12%
Carfilzomib
12%
Chimeric Antigen Receptor
12%
Bispecific Antibody
12%